Erasca has filed a prospectus for a mixed shelf offering, allowing the company to register securities that may be offered from time to time. The filing was submitted to the Securities and Exchange Commission (SEC) on May 8, 2026. This registration provides the company with flexibility to raise capital through various types of securities in the future.

The prospectus does not disclose the specific terms of the offering, including the aggregate amount of securities to be offered or their pricing. A mixed shelf offering enables a company to issue different types of securities, such as common stock, preferred stock, debt securities, or warrants, within a single registration. This approach allows the company to act quickly when market conditions are favorable without needing to file separate registration statements for each offering.

Filing Details

The following table outlines the key details of the filing:

The use of a shelf registration is a common mechanism for companies seeking capital efficiency. It allows management to time the market effectively, potentially securing better pricing for its securities. Until the company prices a specific offering under this shelf, the financial impact on Erasca remains undetermined.

Erasca, Inc. announced updated preliminary Phase 1 data for its pan-RAS molecular glue ERAS-0015, demonstrating a 57% unconfirmed overall response rate in second-line or greater KRAS G12X pancreatic cancer patients. The data, presented from the ongoing AURORAS-1 trial in the U.S., showed encouraging monotherapy responses at the recommended dose for expansion of 32 mg once daily. The company also outlined plans to initiate potentially registration-enabling trials in lung and pancreatic cancers starting in 2027.

The updated results build on the company's April 2026 announcement, including additional patients and longer follow-up. At the recommended dose for expansion of 32 mg once daily, the unconfirmed overall response rate was 57% in patients with KRAS G12X pancreatic ductal adenocarcinoma. Across all doses, all patients with confirmed or unconfirmed responses remained on treatment. At the 32 mg once daily dose, 6 of 7 enrolled patients remained on treatment, while at the 24 mg once daily dose, 6 of 8 enrolled patients remained on treatment.

Safety and Tolerability

ERAS-0015 was generally well-tolerated at the recommended doses for expansion. The frequency and severity of treatment-related adverse events remained consistent with the prior disclosure. Most adverse events were low-grade, with no dose-limiting toxicities observed. The rate of dose interruptions or reductions due to treatment-related adverse events was low, and there were no discontinuations due to treatment-related adverse events. The median relative dose intensity was 100% at both 24 mg once daily and 32 mg once daily.

Combination Potential and Development Plans

The company reported promising combination potential for ERAS-0015 with panitumumab in metastatic colorectal cancer. No dose-limiting toxicities were observed for the combination in the 16 mg cohort during dose escalation in four dose-limiting toxicity-evaluable patients. Backfill enrollment is ongoing in the 16 mg combination cohort, and dose escalation is ongoing with continued enrollment in the 24 mg combination cohort.

Erasca plans to accelerate development in its highest value indications. The company intends to initiate a potentially registration-enabling trial in second-line or greater non-small cell lung cancer in the first half of 2027. A Phase 3 pivotal trial in first-line pancreatic ductal adenocarcinoma is planned for 2027, followed by an additional Phase 3 pivotal trial in RAS-mutant non-small cell lung cancer in the second half of 2027 to the first half of 2028.

Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder, stated that the continued notable responses in pancreatic cancer, along with encouraging data in lung cancer and early combination signals, underscore the broad potential of ERAS-0015. He added that the company is well-positioned to execute its clinical development plan and transition into Phase 3 development.